Our Pricing

Understanding the Saxenda Dose: Complete UK Dosing Schedule Guide

Published on: June 03, 2026

The saxenda dose follows a carefully structured escalation protocol designed to minimise side effects while optimising weight loss outcomes. As a UK-registered pharmacy, we've guided thousands of patients through Saxenda's five-week titration schedule, starting at 0.6mg daily and gradually increasing to the 3mg maintenance dose. Understanding this dosing schedule is essential for achieving the average 8-10% body weight reduction observed in clinical trials.

What Is the Standard Saxenda Dose Schedule?

The saxenda dose escalation follows a precise five-week titration protocol approved by the MHRA for UK patients. Week one begins with 0.6mg injected subcutaneously once daily, increasing by 0.6mg increments each week until reaching the 3mg maintenance dose in week five [1]. This gradual escalation significantly reduces gastrointestinal side effects compared to starting at higher doses.

Each Saxenda pen contains 18mg of liraglutide across 3ml solution, delivering doses from 0.6mg to 3mg in 0.6mg increments. The pen mechanism allows precise dose selection, with each click representing 0.6mg. Patients should inject at the same time daily, regardless of meals, rotating injection sites between abdomen, thigh, and upper arm to prevent lipodystrophy [2].

Clinical experience shows that approximately 85% of patients tolerate the full escalation schedule without requiring dose adjustments. However, if nausea or vomiting occurs during escalation, remaining at the current dose for an additional week before increasing is clinically appropriate, subject to prescriber guidance.

Saxenda Dose Week-by-Week Titration Protocol

Week one requires a 0.6mg saxenda dose administered once daily, allowing your body to adjust to liraglutide's GLP-1 receptor agonist effects. This initial dose activates satiety pathways without overwhelming gastrointestinal tolerance. Week two increases to 1.2mg daily, doubling the dose whilst remaining well below the therapeutic target.

Week three escalates the saxenda dose to 1.8mg daily, week four reaches 2.4mg, and week five achieves the full 3mg maintenance dose. This 3mg daily dose represents the therapeutic level demonstrated in the SCALE trials to produce average weight loss of 8% body weight over 56 weeks [3]. Patients maintain this 3mg dose for the duration of treatment, typically 12 months initially.

Each weekly increase should occur on the same day of the week to maintain consistency. If you miss increasing your dose on the scheduled day, increase it with your next injection rather than waiting another week. The gradual escalation reduces nausea incidence from approximately 48% at immediate 3mg dosing to under 25% with proper titration [4].

Managing Dose Escalation Side Effects

Nausea represents the most common side effect during saxenda dose escalation, typically peaking 2-3 days after each increase and subsiding within one week. Eating smaller, more frequent meals and avoiding high-fat foods significantly improves tolerance. If nausea persists beyond one week at any dose level, consult your prescriber about delaying the next increase.

Approximately 10-15% of patients require extended time at intermediate doses before reaching 3mg. This individualised approach maintains treatment adherence whilst achieving therapeutic benefit, as even sub-maximal doses produce measurable weight loss when combined with lifestyle modification.

How to Adjust Your Saxenda Dose Safely

The saxenda dose should never be increased faster than the standard weekly escalation schedule, as this significantly increases gastrointestinal side effects without improving weight loss outcomes. If you experience persistent nausea, vomiting more than once daily, or severe abdominal discomfort at any dose level, remain at your current dose for an additional 3-7 days before attempting escalation [5].

Dose reduction is rarely necessary once you've reached a tolerated level, but if side effects become intolerable at 3mg, reducing to 2.4mg for one week before re-attempting 3mg is clinically acceptable. Approximately 5% of patients achieve optimal results at 2.4mg rather than the full 3mg maintenance dose, particularly those with lower starting BMI or enhanced dietary adherence.

Never double your saxenda dose to compensate for a missed injection. If you miss a dose and more than 12 hours have passed since your usual injection time, skip that dose entirely and resume your normal schedule the following day. Missing occasional doses does not require restarting the escalation protocol unless you've missed more than three consecutive days.

Saxenda Dose Effectiveness: What the Clinical Data Shows

The 3mg maintenance saxenda dose demonstrated average weight loss of 8.4kg (versus 2.8kg placebo) over 56 weeks in the SCALE Obesity and Prediabetes trial involving 3,731 participants [3]. Approximately 63% of patients on the full dose achieved at least 5% body weight reduction, whilst 33% achieved 10% or greater reduction when combined with reduced-calorie diet and increased physical activity.

Weight loss typically begins during the dose escalation phase, with most patients losing 2-4% of body weight by week eight when reaching the full 3mg dose. Maximum weight loss generally occurs between months 6-8 of continuous treatment at the maintenance saxenda dose. Patients who do not achieve at least 4% weight loss by week 16 at the 3mg dose are unlikely to achieve clinically meaningful outcomes with continued treatment [6].

The dose-response relationship shows significantly better outcomes at 3mg compared to lower doses. In head-to-head comparisons, 3mg daily produced 5.8kg average weight loss versus 4.7kg at 2.4mg and 3.5kg at 1.8mg over 20 weeks, demonstrating the importance of reaching and maintaining the full therapeutic dose.

Long-term Saxenda Dose Maintenance

Maintaining the 3mg saxenda dose beyond one year is appropriate for patients who achieved clinically significant weight loss and require ongoing weight management support. The SCALE Maintenance trial demonstrated that continuing treatment for 56 weeks after initial diet-induced weight loss prevented weight regain significantly better than placebo [7].

Treatment duration should be individualised based on weight loss response, tolerability, and overall metabolic health improvements. Patients should be reviewed by their prescriber every 3-6 months to assess continued appropriateness of the 3mg maintenance dose and evaluate whether treatment goals are being met.

Saxenda Dose Comparison with Other Weight Loss Treatments

The saxenda dose of 3mg liraglutide daily differs fundamentally from semaglutide-based treatments like Wegovy, which uses a different GLP-1 receptor agonist at lower doses. Wegovy's maintenance dose of 2.4mg semaglutide weekly (not daily) produces average weight loss of 12-15% versus Saxenda's 8-10%, though both require similar dose escalation protocols to minimise side effects.

Compared to Mounjaro (tirzepatide), which combines GLP-1 and GIP receptor agonism at maintenance doses of 10-15mg weekly, the saxenda dose represents a first-generation GLP-1 approach. Tirzepatide trials showed 15-22% average weight loss, significantly higher than liraglutide, though Saxenda remains an effective option for patients seeking daily injection control or those who've previously tolerated liraglutide well [8].

Orlistat, a non-injection alternative, works through fat absorption inhibition rather than appetite regulation and produces more modest 3-5% weight loss. The saxenda dose provides superior weight loss outcomes but requires injection administration and costs more than oral alternatives. Treatment selection should consider individual preferences, BMI, comorbidities, and tolerance for injection versus oral therapy.

Getting Your Saxenda Dose at the Cheapest UK Price

Cured Pharmacy offers the saxenda dose at £48.00 per pen, with new patients receiving £20 off their first order using code Weightlossnew, reducing the initial price to £48.00. Each pen contains sufficient medication for approximately 6 days at the 3mg maintenance dose, or longer during the escalation phase when using lower doses.

All Saxenda prescriptions require clinical assessment by our UK-registered prescribers, completed online in under three minutes. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all dispensing, ensuring you receive genuine UK-licensed liraglutide with full regulatory compliance. We provide transparent upfront pricing before consultation, unlike many services that reveal costs only after assessment.

Orders are dispensed from our GPhC-registered pharmacy (9012511) with next-day delivery in discreet packaging. Each shipment includes complete dosing instructions, injection technique guidance, and access to our clinical team for dose escalation questions. Our lowest price guarantee ensures you're accessing the most competitive UK pricing for your saxenda dose whilst maintaining full pharmaceutical standards and prescriber oversight.

Starting Your Saxenda Dose with Cured Pharmacy

Begin by completing our online clinical assessment, which covers your weight history, previous weight loss attempts, current medications, and relevant health conditions. Our prescribers evaluate your suitability for the saxenda dose escalation protocol and provide personalised guidance on managing the titration schedule.

Once approved, your first prescription typically covers the initial escalation period with appropriate pen quantities for weeks 1-5. Subsequent prescriptions focus on the 3mg maintenance dose, with regular prescriber reviews to assess progress and address any dosing concerns. Our team remains available throughout your treatment journey to optimise your saxenda dose schedule for best outcomes.

Scientific References

1. Electronic Medicines Compendium. (2023). Saxenda 6 mg/ml solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines.org.uk. [accessed 13 August 2026]
2. Blonde, L., & Russell-Jones, D. (2009). The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes, Obesity and Metabolism, 11(Suppl 3), 26-34. [accessed 13 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. [accessed 13 August 2026]
4. Lean, M. E., Carraro, R., Finer, N., Hartvig, H., Lindegaard, M. L., Rössner, S., ... & Astrup, A. (2014). Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. International Journal of Obesity, 38(5), 689-697. [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2020). Liraglutide for managing overweight and obesity. NICE Technology Appraisal Guidance [TA664]. [accessed 13 August 2026]
6. Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V., Hale, P. M., & Aronne, L. (2013). Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International Journal of Obesity, 37(11), 1443-1451. [accessed 13 August 2026]
7. le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C., Van Gaal, L., ... & Pi-Sunyer, X. (2017). 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. The Lancet, 389(10077), 1399-1409. [accessed 13 August 2026]
8. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 13 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.